SCHEMBL1163063

SCHEMBL1163063

Cc1nc2cccnc2n1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
KDM4E B2RXH2 2/20 0.50
LMNA P02545 3/20 0.47
RAB9A P51151 2/20 0.47
USP2 O75604 1/20 0.47
ALDH1A1 P00352 3/20 0.46
NPC1 O15118 1/20 0.46
PKM P14618 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
POLB P06746 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR1A P08908 1/20 0.43
HTR2C P28335 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
PDE10A Q9Y233 3/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL17962224 0.98 MAPT (0.49) MAPTKDM4ELMNARAB9AUSP2
SCHEMBL13310868 0.82 MAPT (0.56) MAPTKDM4ELMNARAB9AUSP2
SCHEMBL13052908 0.79 MAPT (0.54) MAPTKDM4ELMNARAB9AUSP2
SCHEMBL14035127 0.78 ALDH1A1 (0.47) MAPTKDM4ELMNARAB9AUSP2
SCHEMBL11011805 0.78 RAB9A (0.46) MAPTKDM4ELMNARAB9AUSP2
SCHEMBL19233674 0.78 KDM4E (0.52) MAPTKDM4ELMNARAB9AUSP2
SCHEMBL1699294 0.78 SMN1; SMN2 (0.55) MAPTKDM4ELMNARAB9AUSP2
SCHEMBL15171062 0.78 RAB9A (0.51) MAPTKDM4ELMNARAB9AUSP2
SCHEMBL18347135 0.78 PDE10A (0.42) MAPTKDM4ELMNAALDH1A1POLB
SCHEMBL19054144 0.78 KDM4E (0.47) MAPTKDM4EALDH1A1NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240074303-A1 DISPLAY APPARATUS SAMSUNG DISPLAY CO., LTD. (KR) 2024-02-29 US disclosed
EP-4242199-A1 USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS XII BASF SE (DE) 2023-09-13 EP disclosed
EP-3873484-B1 NOVEL STING AGONISTS VENENUM BIODESIGN LLC (US) 2023-08-23 EP disclosed
US-11696499-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2023-07-04 US disclosed
US-11696499-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2023-07-04 US disclosed
US-11696496-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2023-07-04 US disclosed
US-11678498-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2023-06-13 US disclosed
US-20220361499-A1 AGRICULTURAL OR HORTICULTURAL INSECTICIDE OR ANIMAL ECTOPARASITE OR ENDOPARASITE CONTROL AGENT EACH COMPRISING A CONDENSED HETEROCYCLIC COMPOUND HAVING A SUBSTITUTED CYCLOPROPANE-OXADIAZOLE GROUP OR A SALT THEREOF AS ACTIVE INGREDIENT, AND METHOD FOR USING THE INSECTICIDE OR THE CONTROL AGENT NIHON NOHYAKU CO., LTD. (JP) 2022-11-17 US disclosed
EP-3889154-A1 HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Wuhan LL Science And Technology Development Co., Ltd. (CN) 2021-10-06 EP disclosed
WO-2021050913-A1 INHIBITORS OF SARM1 DISARM THERAPEUTICS, INC. (US) 2021-03-18 WO disclosed
WO-2003086371-A2 USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed
EP-1326864-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 EP disclosed
WO-2002032900-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed
US-5936083-A BACTERICIDES Uclaf, Roussel (FR) 1999-08-10 US disclosed
EP-0462009-B1 Cephalosporins having in position 3 a propenyl radical substituted by a quaternary ammonium, their process for preparation, their use as medicaments, compositions containing them and intermediates HOECHST MARION ROUSSEL INC (FR) 1998-10-28 EP disclosed
US-5541318-A Cephalosporins ROUSSEL UCLAF (FR) 1996-07-30 US disclosed
US-5416080-A Cephalosporins ROUSSEL-UCLAF (FR) 1995-05-16 US disclosed
US-5397779-A Cephalosporins ROUSSEL-UCLAF (FR) 1995-03-14 US disclosed
US-5373001-A Antibiotics ROUSSEL UCLAF (FR) 1994-12-13 US disclosed
EP-0462009-A1 Cephalosporins having in position 3 a propenyl radical substituted by a quaternary ammonium, their process for preparation, their use as medicaments, compositions containing them and intermediates ROUSSEL UCLAF (FR) 1991-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220361499-A1 AGRICULTURAL OR HORTICULTURAL INSECTICIDE OR ANIMAL ECTOPARASITE OR ENDOPARASITE CONTROL AGENT EACH COMPRISING A CONDENSED HETEROCYCLIC COMPOUND HAVING A SUBSTITUTED CYCLOPROPANE-OXADIAZOLE GROUP OR A SALT THEREOF AS ACTIVE INGREDIENT, AND METHOD FOR USING THE INSECTICIDE OR THE CONTROL AGENT H1-3, H1-0, CBR3 MAPT 4466/4885KDM4E 1428/4885LMNA 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.